Trials / Terminated
TerminatedNCT00397319
Growth Hormone's Effect on the Cardiovascular System
The Role of Growth Hormone in Cardiovascular Health
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 26 (planned)
- Sponsor
- Vanderbilt University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To evaluate specific markers of cardiovascular risk before and after growth hormone replacement therapy in a population of growth hormone deficient adults, as compared to an age, gender, and BMI-matched healthy population.
Detailed description
Growth hormone deficiency (GHD) is associated with increased cardiovascular morbidity and mortality. The effects of such a deficiency include decreased exercise capacity and tolerance, impaired cardiac function, a central fat redistribution, increased peripheral arterial resistance, and an unfavorable lipid profile. These effects have been found to be reversed with appropriate replacement therapy with recombinant human growth hormone. We plan to utilize several experimental systems to further investigate the role of growth hormone (GH) in maintaining cardiovascular health. In particular, we would like to further understand the interaction of GH with Plasminogen-activator-inhibitor-1 (a major activator of the fibrinolytic system) as well as the role of GH in the maintenance of vascular function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Growth Hormone |
Timeline
- Start date
- 2005-08-01
- Completion
- 2006-12-01
- First posted
- 2006-11-09
- Last updated
- 2007-07-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00397319. Inclusion in this directory is not an endorsement.